Compare NLOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | CHRS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.7M | 209.8M |
| IPO Year | 2022 | 2014 |
| Metric | NLOP | CHRS |
|---|---|---|
| Price | $11.58 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 175.0K | ★ 1.1M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 52.20% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $118,915,000.00 | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $0.81 |
| 52 Week High | $34.31 | $2.62 |
| Indicator | NLOP | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 40.92 |
| Support Level | $11.60 | $1.39 |
| Resistance Level | $12.26 | $1.42 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 77.51 | 10.00 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.